CL2016002873A1 - Composición farmacéutica para reducir el daño talámico. - Google Patents

Composición farmacéutica para reducir el daño talámico.

Info

Publication number
CL2016002873A1
CL2016002873A1 CL2016002873A CL2016002873A CL2016002873A1 CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1 CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A CL2016002873 A CL 2016002873A CL 2016002873 A1 CL2016002873 A1 CL 2016002873A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
damage
thalamic damage
reduce
reduce thalamic
Prior art date
Application number
CL2016002873A
Other languages
English (en)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2016002873A1 publication Critical patent/CL2016002873A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE LAQUINIMOD PARA EL USO EN INHIBIR O REDUCIR DAÑO TALAMICO EN VALOR DE REFERENCIA EN UN SUJETO AFECTADO CON UNA ENFERMEDAD O TRASTORNO DIFERENTE A UNA FORMA DE ESCLEROSIS MULTIPLE O UN SINDROME CLINICAMENTE AISLADO, O PARA INHIBIR O REDUCIR TEMBLORES O ESPASTICIDAD.
CL2016002873A 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico. CL2016002873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
CL2016002873A1 true CL2016002873A1 (es) 2017-04-17

Family

ID=50475887

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CL2016002873A CL2016002873A1 (es) 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.

Country Status (18)

Country Link
US (2) US20140107154A1 (es)
EP (1) EP2961406A4 (es)
JP (1) JP2015533163A (es)
KR (1) KR20150080509A (es)
CN (1) CN105263325A (es)
AR (1) AR092993A1 (es)
AU (2) AU2013329348A1 (es)
BR (1) BR112015007782A2 (es)
CA (1) CA2884272A1 (es)
CL (2) CL2015000732A1 (es)
EA (1) EA201590726A1 (es)
HK (1) HK1218865A1 (es)
IL (1) IL237745A0 (es)
MX (1) MX2015004564A (es)
PE (1) PE20151435A1 (es)
SG (1) SG11201501874TA (es)
TW (1) TW201420101A (es)
WO (1) WO2014058979A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
KR20160110395A (ko) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
SG10202102198RA (en) * 2016-09-13 2021-04-29 Intekrin Therapeutics Inc Treatment of multiple sclerosis with chs-131
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276393A1 (en) * 2005-01-13 2006-12-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
KR20090021313A (ko) * 2006-07-17 2009-03-02 노파르티스 아게 면역조절제로서 사용하기 위한 담즙산 아미드의 술포닐아미노카르보닐 유도체
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
CA2820586A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
ES2602794T3 (es) * 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
AU2012322706A1 (en) * 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple

Also Published As

Publication number Publication date
CA2884272A1 (en) 2014-04-17
EP2961406A2 (en) 2016-01-06
IL237745A0 (en) 2015-05-31
KR20150080509A (ko) 2015-07-09
EP2961406A4 (en) 2017-01-04
AU2017203896A1 (en) 2017-06-29
TW201420101A (zh) 2014-06-01
CN105263325A8 (zh) 2017-07-14
CN105263325A (zh) 2016-01-20
AR092993A1 (es) 2015-05-13
PE20151435A1 (es) 2015-10-15
HK1218865A1 (zh) 2017-03-17
SG11201501874TA (en) 2015-05-28
JP2015533163A (ja) 2015-11-19
EA201590726A1 (ru) 2015-10-30
US20160296511A1 (en) 2016-10-13
MX2015004564A (es) 2015-07-21
WO2014058979A2 (en) 2014-04-17
BR112015007782A2 (pt) 2017-07-04
WO2014058979A8 (en) 2015-04-16
AU2013329348A1 (en) 2015-05-28
WO2014058979A3 (en) 2015-08-20
CL2015000732A1 (es) 2015-08-07
US20140107154A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
HRP20181287T1 (hr) Aminoheteroarilbenzamidi kao inhibitori kinaze
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112015002738A2 (pt) composto , e , composição farmacêutica
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
GB2529325B (en) Multi-tenancy support for enterprise social business computing
EP3059271A4 (en) Fluorine-containing compound, composition for forming hard coat layer, and article having hard coat layer
EP2966110A4 (en) FLUOROUS ETHER COMPOUND, COMPOSITION FOR FORMING A HARD COATING LAYER AND ARTICLES WITH A HARD COATING LAYER
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
EP3000094A4 (en) Medication workflow management
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
GB201517616D0 (en) Social project management
GB2500292B (en) Hash-based Managing of Storage Identifiers
EP2956471A4 (en) IL-1BETA INHIBITOR COMPOSITION AND USE THEREOF
BR112015002646A2 (pt) composto e composição farmacêutica
BR112014000232A8 (pt) primeira composição, segunda composição e artigo
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
BR112013019061A2 (pt) composto inibidor da caspase-2, composição farmacêutica e uso de um composto
ZA201504080B (en) Combination medicament comprising phenylephrine and paracetamol
BR112014016122A2 (pt) composto, e, composição farmacêutica
BR112013019283A2 (pt) composto, fármaco, composição farmacêutica e uso
AU2014351069B2 (en) Social media platform
BR112016008035A2 (pt) composição, uso da composição
BR112015001169A2 (pt) polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo